BioCryst Expects NIAID To Stop COVID Indication For Galidesivir
December 22, 2020 at 09:25 AM EST
BioCryst Pharmaceuticals announced that it expects the National Institute of Allergy and Infectious Diseases to discontinue the pursuit of a COVID-19 indication for galidesivir.
